Dynavax Technologies (DVAX) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary

Policy and market environment

• HEPLISAV-B is considered insulated from policy volatility due to its adult focus and robust safety data.

• Universal vaccination recommendation in 2022 supports long-term growth and public health goals.

• Ongoing monitoring of policy environment ensures readiness for challenges and opportunities.

Market share and growth outlook

• Market share reached 44% exiting Q3 2024, up from 41% the prior year, with annual growth expected to continue.

• Long-term guidance targets at least 60% market share by 2030, driven by strong performance in retail and IDN channels.

• Retail and IDN channels reported 55%-56% share, outpacing overall market growth.

• Market penetration assumptions for 2030 are based on 40%-50% cumulative coverage, with $900 million revenue target.

• Revaccination practices and unvaccinated populations provide ongoing growth opportunities.

Capital allocation and share repurchase

• $200 million share repurchase program authorized, with $100 million executed via accelerated plan.

• Full repurchase expected within 12 months, balancing near- and long-term value creation.

• Discontinued Tdap program to focus resources on more competitive and promising assets.

• Shingles program supported through next data readout in H2 2025.